Zhou SL, Xin HY, Sun RQ, et al. - In view of the correlation of KRAS variants with tumor progression, researchers sought to ascertain their prevalence and association with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma (ICC).

• A total of 1,024 patients were included in this cohort study.

• Performing whole-exome sequencing, targeted sequencing, and Sanger sequencing, researchers identified a total of 14 different subtypes of KRAS somatic variants affecting 127 patients with ICC (12.4%), including G12D (43.3%), G12V (19.7%), G12C (7.1%), and G13D (6.3%).

• Findings revealed worse overall and disease-free survival in independent association with G12 KRAS variants but not non-G12 KRAS variants.

• The G12V KRAS variant was identified to be the strongest prognostic determinant for the worst overall and disease-free survival.